Diagnosing Neuropsychiatric SLE (5.23.2025)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com - including views on the vagus nerve, NPSLE and CAR-T mania.
IMPACT Study - Certolizumab Efficacy in APS Pregnancies
Lupus Nephritis
2025 ACR Guideline for the Treatment of SLE
The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment guidelines and consensus-based good practice statements, applicable to children and adults with SLE.
Overall, the goals of SLE management are to achieve remission or a low level disease activity, reduce morbidity and mortality, and minimize treatment-related adverse events.
For treatment of SLE, they recommend universal use of hydroxychloroquine, minimizing glucocorticoid exposure, and early introduction of conventional and/or biologic immunosuppressive therapies.
Genetic Link to CPPD
In a first-of-its-kind genome-wide association study (GWAS) researchers have discovered two genes, RNF144B and ENPP1, that cause calcium pyrophosphate deposition (CPPD) disease in Americans of European and African descent. This crystalline arthritis is caused by calcium pyrophosphate (CPP) crystal deposition in joints.
Contemporary lupus nephritis treatment
How Living With Childhood-Onset Lupus Impacts Mental Health
SLE Treatment Landscape: Abundance or Overload?
50 Year Perspective on Lupus
Valves Gone Wild in SLE
Belimumab in SLE with Mucocutaneous or Vasculitis Findings
Do SGLT2 and GLP-1 therapies have a role in Lupus?
Moneyball Rheumatology (5.30.2025)
Dr. Jack Cush reviews the book/movie, "Moneyball" and a suggests moneyball strategy is needed to find next level responses for our patients.
Patient Phenotypes Within the Clinical Program of an IL-23 Inhibitor for PsA
Rules on Mycophenolate Use in SLE
Dr. Diane Kamen. a rheumatologist and lupologist from the Medical University of South Carolina in Charleston, South Carolina, discusses the use of mychophenolate in the management of systemic lupus.
Denosumab and Osteoporosis - A JAMA Review
An overview of denosumab use in osteoporosis (OP) by Bauer and Ensrud was published in JAMA.
Autoimmunity Rising in Expectant Mothers
Lancet Rheumatology has published a UK study showing a significant increased in the number of expectant mothers beginning their pregnancies with autoimmune conditions.
The MuM-PreDiCT project run by the University of Birmingham, analyzed the electronic healthcare records from CPRD (2000-2021). This included 185 208 pregnancies in 100 655 women diagnosed with autoimmune disease.
Methotrexate Fails in Knee Osteoarthritis
Type 2 SLE: Insights from a Biopsychosocial Framework
HLA-B27 Testing in Practice
Analysis of testing for human leukocyte antigen B27 (HLA-B27) in a teaching center shows HLA-B27 testing was frequently performed by rheumatologists and nonrheumatologists for a broad spectrum of indications and primarily as a screening test.
Data derived from the Mass General Brigham healthcare system, examined HLA-B27 testing and clinical associations between 1/1/2022 to 12/31/2022. Rheumatology referrals were calculated for HLA-B27 positive and negative patients.
Psoriatic Arthritis at Risk for Interstitial Lung Disease
MTX Fails Knee OA (6.6.2025)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com
2025 EULAR/ACR Risk Stratification Criteria for At-Risk Arthralgia
Secukinumab Use in Refractory Giant Cell Arteritis
In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab. While we await the results of a larger phase 3 trial, there is a 6 patient case series also suggesting the efficacy of IL-17 inhibition in GCA, not responding to TCZ.
A case series of six GCA patients from three centres in Italy. All were treated with secukinumab (300 mg SC weekly for four weeks, then 300 mg monthly). Clinical outcomes were assessed at six months.
A Closer Look at Psoriatic Arthritis Outcome Measures and Disease Control
Intraarticular IL-1Ra Gene Therapy in Knee Osteoarthritis
De la Vega et al. have published in Science Translational Medicine the efficacy of an IL-1Ra gene therapy in adults with knee osteoarthritis (OA).
In a dose-escalation trial in nine participants, they observed that a single intra-articular injection of the gene product led to an increase in IL-1Ra in the synovial fluid that remained elevated for up to a year. There were no serious adverse events related to the gene delivery.
Transcranial Stimulation is Effective in Fibromyalgia
A randomized, controlled clinical trial in fibromyalgia (FM) has shown the efficacy of transcranial direct current stimulation (A-tDCS) (along with exercise and pain neuroscience education [PNE]), in alleviating the pain.
Review Anifrolumab-fnia Clinical Data | Explore What’s New With Management Recommendations
Secukinumab promise in PMR is real
